Literature DB >> 30740424

Translating L-2-HG to kidney cancer at the bench and bedside.

Omran Abu Aboud1, Robert H Weiss1,2,3.   

Abstract

Entities:  

Year:  2018        PMID： 30740424      PMCID： PMC6330595          DOI： 10.21037/atm.2018.11.41

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  11 in total

1.  The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate.

Authors:  Vicki J Hwang; Jeffrey Kim; Amy Rand; Chaozhe Yang; Steve Sturdivant; Bruce Hammock; P Darwin Bell; Lisa M Guay-Woodford; Robert H Weiss
Journal:  Am J Physiol Renal Physiol       Date:  2015-07-08

2.  L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.

Authors:  Eun-Hee Shim; Carolina B Livi; Dinesh Rakheja; Jubilee Tan; Daniel Benson; Vishwas Parekh; Eun-Young Kho; Arindam P Ghosh; Richard Kirkman; Sadanan Velu; Shilpa Dutta; Balachandra Chenna; Shane L Rea; Robert J Mishur; Qiuhua Li; Teresa L Johnson-Pais; Lining Guo; Sejong Bae; Shi Wei; Karen Block; Sunil Sudarshan
Journal:  Cancer Discov       Date:  2014-09-02       Impact factor: 39.397

Review 3.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.

Authors:  Patrick S Ward; Craig B Thompson
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

4.  IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Authors:  Chao Lu; Patrick S Ward; Gurpreet S Kapoor; Dan Rohle; Sevin Turcan; Omar Abdel-Wahab; Christopher R Edwards; Raya Khanin; Maria E Figueroa; Ari Melnick; Kathryn E Wellen; Donald M O'Rourke; Shelley L Berger; Timothy A Chan; Ross L Levine; Ingo K Mellinghoff; Craig B Thompson
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

Review 5.  Metabolic reprogramming in clear cell renal cell carcinoma.

Authors:  Hiromi I Wettersten; Omran Abu Aboud; Primo N Lara; Robert H Weiss
Journal:  Nat Rev Nephrol       Date:  2017-05-08       Impact factor: 28.314

6.  MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.

Authors:  Emelyn H Shroff; Livia S Eberlin; Vanessa M Dang; Arvin M Gouw; Meital Gabay; Stacey J Adam; David I Bellovin; Phuoc T Tran; William M Philbrick; Adolfo Garcia-Ocana; Stephanie C Casey; Yulin Li; Chi V Dang; Richard N Zare; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-11       Impact factor: 11.205

Review 7.  The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.

Authors:  Iman Abou Dalle; Courtney D DiNardo
Journal:  Ther Adv Hematol       Date:  2018-06-01

8.  Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.

Authors:  Omran Abu Aboud; Samy L Habib; Josephine Trott; Benjamin Stewart; Sitai Liang; Abhijit J Chaudhari; Julie Sutcliffe; Robert H Weiss
Journal:  Cancer Res       Date:  2017-10-11       Impact factor: 12.701

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.

Authors:  Lucia Salamanca-Cardona; Hardik Shah; Alex J Poot; Fabian M Correa; Valentina Di Gialleonardo; Hui Lui; Vesselin Z Miloushev; Kristin L Granlund; Sui S Tee; Justin R Cross; Craig B Thompson; Kayvan R Keshari
Journal:  Cell Metab       Date:  2017-10-19       Impact factor: 31.373
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.